腾博会官网·[中国]-诚信为本,专业服务!

VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR “GARSORASIB TABLET (D-1553)”

VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING “ANLOTINIB HYDROCHLORIDE CAPSULES”, “TQB2916 (CD40 AGONIST)” AND “FHND6091 (PROTEASOME INHIBITOR)” WERE PRESENTED AT 2024 AACR

VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA

VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

FINAL DIVIDEND FOR 2023

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF “IOPROMIDE INJECTION”